Extend your brand profile by curating daily news.

HeartBeam Partners with HeartNexus to Expand Remote Cardiac Monitoring Services

By FisherVista

TL;DR

HeartBeam's partnership with HeartNexus provides competitive advantage through 24/7 cardiology services that capture patients outside traditional healthcare settings.

HeartBeam's patented 3D technology captures 30-second cable-free ECG recordings that transmit data to HeartNexus cardiologists for immediate interpretation and analysis.

This partnership makes cardiac monitoring accessible beyond medical facilities, improving heart health management and potentially saving lives through timely interventions.

HeartBeam's FDA-cleared 3D ECG technology can record heart signals from three directions and synthesize them into a 12-lead ECG anywhere.

Found this article helpful?

Share it with your network and spread the knowledge!

HeartBeam Partners with HeartNexus to Expand Remote Cardiac Monitoring Services

HeartBeam Inc. (NASDAQ: BEAT) has announced a strategic partnership with HeartNexus Inc., a network of board-certified cardiologists, to deliver comprehensive remote cardiology services. This collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional healthcare settings, marking a significant advancement in accessible cardiac care.

The partnership leverages HeartBeam's patented 3D technology, which allows patients to capture 30-second, cable-free electrocardiogram (ECG) recordings whenever symptoms occur. These recordings are transmitted directly to HeartNexus cardiologists for immediate interpretation, providing real-time cardiac assessment without requiring hospital or clinic visits. Robert Eno, CEO of HeartBeam, stated that working with HeartNexus accelerates the company's mission to make medical-grade cardiac monitoring accessible beyond medical facility walls.

HeartBeam's technology represents a breakthrough in cardiac monitoring as the first cable-free device capable of collecting ECG signals in three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review. The company holds over 20 issued patents related to this technology enablement.

The expanded ecosystem created by this partnership includes future integration of artificial intelligence wellness features and wearable technology capabilities. This development could significantly impact how cardiac conditions are detected and monitored, potentially reducing emergency room visits and hospitalizations through early intervention. Patients with chronic cardiac conditions or those at risk of cardiac events may benefit from continuous monitoring without disrupting their daily activities.

For additional information about HeartBeam's developments, investors can access the company's newsroom at https://ibn.fm/BEAT. The full press release detailing this partnership is available at https://ibn.fm/HqwuQ. This collaboration between medical technology innovation and specialized cardiology services represents a meaningful step toward democratizing cardiac care and making advanced medical monitoring available to patients wherever they are located.

The integration of real-time cardiology feedback with portable ECG technology addresses a critical gap in current healthcare delivery, particularly for rural patients or those with mobility limitations. By enabling immediate cardiac assessment during symptomatic episodes, this partnership could lead to faster diagnosis and treatment of potentially life-threatening conditions. The technology's ability to capture comprehensive 3D ECG data outside clinical settings may also provide physicians with more accurate information about cardiac events as they occur naturally, rather than in artificial clinical environments.

blockchain registration record for this content
FisherVista

FisherVista

@fishervista